Literature DB >> 19604879

Increased CSF levels of endorphines in chronic psychosis.

L Terenius1, A Wahlström, L Lindström, E Widerlöv.   

Abstract

The levels of two endorphines, endogenously occurring morphinomimetic peptides, were measured in serial samples of CSF from seven psychiatric patients. Four cases with chronic schizophrenia were studied before and after treatment with the antipsychotic agent clozapine (Leponex). Supernormal fraction II levels were found on at least one sampling occasion in each patient. Two patients, who responded well to clozapine treatment, showed a clear-cut drop in fraction II levels, whereas two patients showed increased levels which paralleled a deterioration of the schizophrenic symptoms. Three manic-depressive cases showed abnormally high levels of endorphine fraction I in the manic phase which declined during normal or depressed phases. Levels of fraction II varied in a less consistent manner and appeared to be at maximum during the apparently normal phases. Although preliminary, the data indicate that endorphines may reach supernormal levels in patients with chronic psychoses.

Entities:  

Year:  1976        PMID: 19604879     DOI: 10.1016/0304-3940(76)90086-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

1.  Opioid peptides, brain and behaviour: a brief review.

Authors:  R J Rodgers
Journal:  Ir J Med Sci       Date:  1978-08       Impact factor: 1.568

2.  Specific opioid-amphetamine interactions in the caudate putamen.

Authors:  S K Woo; R J Hitzemann; H H Loh
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

3.  The effect of neuroleptic treatment and of high dosage diazepam therapy on beta-endorphin immunoreactivity in plasma of schizophrenic patients.

Authors:  C Gramsch; H M Emrich; S John; S Haas; H Beckmann; M Zaudig; D von Zerssen
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

4.  Effect of naloxone on the state of patients with endogenous psychoses.

Authors:  R R Lideman; G P Panteleeva; F E Vartanyan; B S Belyaev
Journal:  Neurosci Behav Physiol       Date:  1984 Nov-Dec

Review 5.  Enkephalins and Endorphins. Clinical, pharmacological and therapeutic implications.

Authors:  D L Copolov; R D Helme
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

6.  Mianserin reduces plasma levels of beta-endorphin immunoreactivity in depressed patients.

Authors:  F Drago; V M Wiegant; G Sapienza; E Aguglia; V Rapisarda; U Scapagnini
Journal:  Experientia       Date:  1982-06-15

7.  The effects of naloxone on methylphenidate-induced mood and behavioral changes: a negative study.

Authors:  L Y Huey; D S Janowsky; L L Judd; N A Roitman; P L Clopton; D Segal; L Hall; D Parker
Journal:  Psychopharmacology (Berl)       Date:  1980-02       Impact factor: 4.530

8.  Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.

Authors:  R Weizman; A Weizman; S Tyano; G Szekely; B A Weissman; Y Sarne
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Naloxone-induced reversal of schizophrenic hallucinations.

Authors:  L M Gunne; L Lindström; L Terenius
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

10.  Sensitivity in vivo of central alpha 2- and opiate receptors after chronic treatment with various antidepressants.

Authors:  J J Scuvée-Moreau; T H Svensson
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.